Allos Therapeutics files $150 million shelf covering stock, warrants

By Devika Patel

Knoxville, Tenn., July 20 - Allos Therapeutics, Inc. filed a $150 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers common stock, preferred stock, depositary shares, debt securities, warrants and units, along with 26,124,430 common shares to be offered by selling shareholders.

The securities may be structured as convertibles.

Proceeds will be used for activities relating to preparations for the potential commercial launch of pralatrexate, clinical and preclinical research and development of pralatrexate, working capital and general corporate purposes.

Allos is a biopharmaceutical company based in Westminster, Colo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.